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11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) catalyzes the conversion of inactive glucocorticoids to active
glucocorticoids and plays an important role in the development of obesity and metabolic syndrome. 11b-HSD1 activ-
ity is lower in liver and higher in omental adipose tissue of obese rodent models like obese zucker rats, Ob/Ob and
db/db mice. Here, we report the 11b-HSD1 activity in liver and adipose tissue of lean and obese rats of WNIN/Ob
strain, a new genetic rat model of obesity. 11b-HSD1 activity in liver, omental and subcutaneous adipose tissues of
3 month-old male WNIN/Ob lean and obese rats was assayed. As observed in other rodent models, 11b-HSD1 activity
was lower in liver and higher in omental adipose tissue. In contrast to other rodent obese models, WNIN/Ob obese
rats had elevated 11b-HSD1 activity in subcutaneous adipose tissue, which is in line with the observation in human
obesity. Here, we conclude that dysregulation of 11b-HSD1 in WNIN/Ob obese rat model is identical to human
obesity, which makes it an excellent model for studying the effect of 11b-HSD1 inhibitors in ameliorating obesity and
metabolic syndrome.
Introduction
Glucocorticoids are essential for the regulation of metabo-
lism, normal functioning of nervous, cardiovascular, skele-
tal and immune systems. They are also implicated in the
pathogenesis of obesity and metabolic syndrome as evi-
denced by the fact that, elevated systemic glucocorticoid
concentration in Cushing’s syndrome results in the devel-
opment of metabolic syndrome including visceral obesity.
The role of plasma glucocorticoids in the development of
idiopathic obesity is not clear, as their levels are not
altered or sometimes even low in obese patients [1].
Tissue sensitivity to glucocorticoids depends on
plasma hormone levels, density of glucocorticoid recep-
tors and local metabolism of glucocorticoids by 11b-
hydroxysteroid dehydrogenases. 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1) catalyzes the conver-
sion of inactive glucocorticoids (cortisone in humans
and 11-dehydrocorticosterone in rodents) to active
glucocorticoids (cortisol in humans and corticosterone
in rodents) [2]. It is highly expressed in liver, adipose
tissue and brain [2]. Another enzyme, 11b-HSD2 cata-
lyses the reverse reaction and expressed in distal
nephron, sweat and salivary glands [3].
Recently, it has been reported that 11b-HSD1 plays an
important role in the development of obesity and insulin
resistance. In obese zuckar rats and in obese human
subjects, 11b-HSD1 activity is higher in adipose tissue,
where as in liver it is low [4-6]. The role of 11b-HSD1
in obesity and metabolic syndrome is further supported
by the transgenic animal model studies. Adipose-specific
overexpression of 11b- H S D 1i nm i c er e s u l t e di nt h e
development of majority of metabolic syndrome features
including visceral obesity and insulin resistance [7],
where as 11b-HSD1 knock-out in mice resulted in the
development of resistance to diet-induced obesity [8].
Recently, selective inhibitors of 11b-HSD1 are developed
to treat obesity and metabolic syndrome.
Rodent models of obesity provide valuable information
on the molecular mechanisms underlying the development
of obesity and its associated complications. WNIN/Ob rat
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rat colony at National centre for Laboratory Animal
Sciences (Hyderabad, India) [9]. They exhibited all bio-
chemical characteristics of leptin-resistant obese zuckar
rats. These rats are hyperphagic, hyperinsulinemic, hyper-
leptinemic and have dyslipidemia [9]. Preliminary studies
on WNIN/Ob obese rats show no molecular defects in
leptin and leptin receptor [unpublished data]. Further,
molecular mutation leading to the development of obesity
in these obese rats is under investigation.
Here, we hypothesize that WNIN/Ob obese rats have
altered 11b-HSD1 enzyme activity in liver and adipose
tissue as observed in other obese rodent models. To test
our hypothesis, we studied the 11b-HSD1 enzyme activ-
ity in liver, adipose tissue and skeletal muscle of
3 month-old WNIN/Ob lean and obese rats.
Materials and methods
Animals
3 month-old WNIN/Ob male lean and obese rats (n = 6)
were obtained from National Centre for Laboratory Ani-
mal Sciences (NCLAS, India) and study was approved by
Institutional Animal Ethical Committee. Animals were
acclimatized in individual cages under controlled condi-
tions of temperature (22 ± 1°C), humidity (50-60%) and
light (12:12 h light-dark cycle). Stock diet and water were
provided ad libitum. After overnight fasting, blood was
collected and the animals were sacrificed by decapitation.
Tissues were dissected out, weighed and stored at -80°C
until the analysis.
Adiposity Index (%)
Adiposity index was calculated by dividing total weight
of omental, retroperitoneal and epididymal adipose tis-
sue with the total bodyweight and multiplied by 100.
Plasma parameters
Plasma corticosterone (Siemens, Los Angeles, USA),
insulin (BARC, India) and leptin (Linco Research, USA)
levels were measured by radioimmunoassay (RIA).
Plasma glucose and triglyceride levels were measured by
Commercial Kits (Biosystems, Spain). Tumor necrosis
factor-a (TNF- a), Interleukin-6 (IL-6) and Macrophage
chemoattractant protein-1 (MCP-1) were estimated by
Milliplex Rat cytokine immunoassay kit (Millipore, USA).
Insulin resistance and glucose tolerance
Insulin resistance was assessed from homeostasis model
assessment of insulin resistance (HOMA-IR). HOMA-IR
was calculated from fasting glucose and insulin values
using the following formula.
HOMA IR fasting insulin U ml fasting glucose mmol l −= [] × [] (/ / )       / / 22.5
Oral glucose tolerance test was performed to measure
the glucose tolerance. After an overnight fast, glucose
(200 g/l) was administered oro-gastrically at a dose of
2.0 g/kg body weight and blood samples were collected
from supraorbital at 0, 30, 60 and 120 min. Glucose and
insulin levels were measured at all time points.
Glucose tolerance was calculated during OGTT by
calculating Area under curve (AUC) for insulin and glu-
cose by the trapezoidal method [10].
11b-HSD1 activity
11b-HSD1 functions as a reductase in vivo, reactivating
corticosterone from inactive 11-dehydrocorticosterone.
However, in tissue homogenates, dehydrogenase activity
predominates, hence 11b-HSD1 activity was measured
by conversion of corticosterone to 11-dehydrocorticos-
terone [11]. Post nuclear fractions from liver and omen-
tal adipose tissue were prepared by centrifuging tissue
homogenate at 1000 g for 20 min. 11b-HSD1 activity
was measured in post nuclear fractions of liver and
omental adipose tissue by incubating in duplicates at
37° C, in Krebs-Ringer buffer containing 0.2% glucose,
1 mM NADP and 50 nM 1, 2, 6, 7-[
3H4] corticosterone
(Amersham, UK). Conditions were optimized to ensure
first order kinetics, by adjusting protein concentrations
for liver (40 μg/ml), adipose tissue (1 mg/ml) and skele-
tal muscle (1 mg/ml). After incubation (30 min for liver
and 6 h for adipose tissue and skeletal muscle), steroids
were extracted with ethyl acetate. Ethyl acetate was eva-
porated under dry nitrogen and steroids were resus-
pended in mobile phase (50% water, 30% acetonitrile
and 20% methanol). Steroids were separated by HPLC
using reverse phase C18 column and radioactive counts
from substrate and product peaks were calculated by
online scintillation counter (IN/US systems, UK).
Enzyme activity was expressed as percentage of sub-
strate conversion.
Statistical analysis
Results were expressed as means±S.E of six animals
from each phenotype. Statistical significance was deter-
mined by student’s t-test and comparisons were made
between lean and obese phenotype.
Results
Body weights, tissue weights and adiposity index
At 3-months of age, WNIN/Ob obese rats had signifi-
cantly higher bodyweights (1.7 fold) as compared to
their lean counter parts (Table 1). Adiposity index was
significantly higher in obese rats (5.4 fold) as compared
to their age and sex-matched lean rats (Table 1).
Weights of liver, retroperitoneal, epididymal and omen-
tal fat depots were also significantly higher (1.7 fold, 5.4
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compared to lean rats (Table 1). Adrenal weights were
significantly higher (1.3 fold) in obese rats as compared
to lean rats, where as adrenal to bodyweight ratio were
significantly lower (0.7 fold) in obese rats as compared
to lean rats (Table 1).
Plasma parameters
Plasma corticosterone levels were significantly elevated
(2 fold) in obese rats as compared to those of lean rats
(Table 2). Fasting insulin and leptin levels were also sig-
nificantly higher (29.4 and 14.2 fold respectively) in
obese rats compared to lean rats (Table 2). Plasma tri-
glyceride levels were significantly higher (4.5 fold) in
obese rats as compared to lean rats (Table 2). There
were no significant changes in the plasma levels of
MCP-1 and IL-6 in obese rats as compared to their lean
counter parts (Table 2). Although TNF-a level was
detectable in lean rats, it was not in detectable range in
obese rats (Table 2).
Insulin resistance and glucose tolerance
Insulin resistance calculated by HOMA-IR is signifi-
cantly higher (37 fold) in obese rats compared to age
and sex-matched lean rats (Table 2). Glucose AUC and
insulin AUC were significantly higher (1.5 fold and 6.2
fold respectively) in obese rats compared to lean rats
(Table 2). Glucose to insulin AUC ratio was significantly
lower (4.9 fold) in obese rats compared to lean rats
(Table 2).
11b-HSD1 activity in omental and subcutaneous
adipose tissue
11b-HSD1 activity was significantly higher (4.4 fold, 2.8
fold respectively) in omental and subcutaneous adipose
tissues of 3-month old WNIN/Ob obese rats as compared
to those of age and sex-matched lean rats (Figure 1A&1B).
11b-HSD1 activity in liver and skeletal muscle
11b-HSD1 activity was significantly lower (0.6 fold) in
liver of obese rats as compared to that of age and sex-
matched lean rats (Figure 1C). Skeletal muscle (quadri-
ceps) 11b-HSD1 activity was not different between
3 month old WNIN/Ob lean and obese rats (Figure 1D).
Discussion
In this study, we reported 11b-HSD1 enzyme activity in
the peripheral tissues of novel genetically-obese rats of
WNIN/Ob strain. WNIN/Ob obese rats had higher
plasma corticosterone levels and heavier adrenal glands,
indicating elevated hypothalamus-pituitary-adrenal
(HPA) axis activity. They also have lower11b-HSD1
activity in liver and higher activity in omental and sub-
cutaneous adipose tissue. To our knowledge, this is the
first genetic rodent model of obesity, exhibiting higher
11b-HSD1 activity in subcutaneous adipose tissue.
Glucocorticoids play an important role in adipocyte
biology. Active glucocorticoids, cortisol (in humans) and
corticosterone (in rodents) are essential for the differen-
tiation of pre-adipocytes into mature adipocytes [12].
11b-HSD1 in adipose tissue is known to increase the
local concentration of active glucocorticoids and thereby
induce preadipocyte differenti a t i o n .T h i si sf u r t h e rs u p -
ported by cell culture studies, where 11b-HSD1 inhibi-
tion has been shown to decrease cortisone-induced
differentiation of pre-adipocytes [13]. Further, the role of
11b-HSD1 in adipocyte differentiation and in obesity is
confirmed by transgenic studies. Transgenic mice over-
expressing 11b-HSD1 in adipose tissue have developed
visceral obesity with increased preadipocyte differentia-
tion [7]. In leptin-resistant obese zucker rats, 11b-HSD1
activity is elevated in omental adipose tissue and no
change is observed in subcutaneous adipose tissue [4]. In
leptin-deficient ob/ob mice and in leptin-resistant db/db
mice, 11b-HSD1 activity is higher in omental adipose
Table 1 Physical parameters in 3 month-old WNIN/Ob
lean and obese rats
Lean (n = 6) Obese (n = 6)
Body wt (g) 307 ± 21 543 ± 13*
Adrenal wt (mg) 37.8 ± 1.9 48.0 ± 1.5*
Adrenal/body wt 0.12 ± 0.004 0.09 ± 0.004*
Adiposity index (%) 1.0 ± 0.03 5.60 ± 0.04*
Liver (g) 10.3 ± 0.37 17.6 ± 0.04*
Omental adipose tissue (g) 0.36 ± 0.04 1.96 ± 0.06*
Epididymal adipose tissue (g) 1.44 ± 0.12 10.5 ± 0.08*
Retroperitoneal adipose tissue (g) 1.84 ± 0.24 15.8 ± 0.04*
Values are mean± S.E of 6 rats. Values with * mark are significant at P < 0.05
level (by student’s t test). Comparisons were made between lean and obese
phenotypes.
Table 2 Plasma parameters in 3 month-old WNIN/Ob lean
and obese rats
Lean (n = 6) Obese (n = 6)
Corticosterone (ng/ml) 213 ± 34 433 ± 50*
Insulin (μU/ml) 7.0 ± 3.6 206 ± 23*
Triglycerides (mg/dl) 46.5 ± 3.0 212 ± 29*
Glucose (mg/dl) 80.0 ± 2.0 86.0 ± 4.7
HOMA-IR 1.4 ± 0.8 52.5 ± 7.0*
Glucose AUC (mmol/l) 304 ± 13 472 ± 31*
Insulin AUC (μU/ml) 5.1 ± 1.2 32 ± 2.8*
Glucose AUC/Insulin AUC (× 1000) 74 ± 14 15 ± 1.4*
Leptin (ng/ml) 1.0 ± 0.1 14.2 ± 1.8*
TNF-a (pg/ml) 3.0 ± 1.6 Nd
IL-6 (ng/ml) 191 ± 62 57.5 ± 35
MCP-1 (μg/ml) 0.3 ± 0.1 2.5 ± 2.3
Values are mean± S.E of 6 rats. Values with * mark are significant at P < 0.05
level (by student’s t test). Comparisons were made between lean and obese
phenotypes. Nd, non-detectable.
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In recently reported polygenic obese mice model and in
diet-induced obese mice, 11b-HSD1 activity is lower
in omental and subcutaneous adipose tissue [14,15].
In human obesity, 11b-HSD1 activity is higher in subcu-
taneous adipose tissue, however in omental adipose tissue
the observations are inconsistent [5,6]. The newly studied
WNIN/Ob obese rat had elevated 11b-HSD1 activity in
omental adipose tissue. They also had higher enzyme
activity in subcutaneous tissue, which is contrast to the
observations made with other obese rodent models, and
in agreement with the observations in human obesity.
Although these obese rats had higher enzyme activity in
omental and subcutaneous adipose tissue under fasting
condition, interestingly, the enzyme activity is decreased
significantly in fed-state as compared to lean rats (unpub-
lished data).
In addition to the gene mutation that caused obesity,
the observed higher 11b-HSD1 activity in omental and
subcutaneous adipose tissue, might contribute to the
development of obesity in this model. The exact
mechanism responsible for the observed higher 11b-
HSD1 activity in adipose tissue of WNIN/Ob obese rats
can not be explained, unless the mutation is identified.
However, the observed higher plasma corticosterone,
insulin and leptin levels might be responsible for
enhanced 11b-HSD1 activity, as these molecules upregu-
late 11b-HSD1 expression in adipocytes [16-18].
Glucocorticoids antagonize insulin signaling in various
tissues and thus implicated in the development of insulin
resistance [19]. 11b-HSD1 negatively influences tissue
insulin sensitivity by generating local active glucocorti-
coids. 11b-HSD1 knockout mice have improved insulin
sensitivity, on the contrary transgenic overexpression of
11b-HSD1 in adipose tissue of mice results in insulin
resistance [7,20]. In obese zuckar rats, increased 11b-
HSD1 activity in adipose tissue is associated with elevated
fasting plasma insulin level [4]. Similar to obese zucker
rat, WNIN/Ob obese rats have increased peripheral insu-
lin resistance as indicated by elevated fasting insulin,
HOMA-IR and increased glucose AUC. Despite of
decreased peripheral insulin sensitivity, WNIN/Ob obese
rats are not glucose intolerant, as glucose level reaches to
normal at the end of second hour after oral glucose chal-
lenge (data not shown). As the obese rats have elevated
11b-HSD1 activity in adipose tissue, increased active
Figure 1 11b-HSD 1 activity in 3 month-old male WNIN/Ob lean and obese rats. (A). Omental fat. (B). Subcutaneous fat. (C). Liver. (D).
Quadriceps muscle. Values are means ± S.E for 6 rats. Mean values with * mark are significant at P < 0.05 level (by student’s t test). Comparisons
were made between lean and obese phenotypes.
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the observed insulin resistance in this model.
Adipose tissue secrets various signaling molecules
including cytokines like TNF-a and IL-6 [21]. Previous
studies reported elevated levels of plasma TNF- a and
IL-6 in obese rodent models and in humans, which are
implicated in the development of obesity induced insulin
resistance and diabetes [22,23]. Transgenic mice over-
expressing 11b-HSD1 in adipose tissue has elevated
TNF- a mRNA and plasma TNF- a,w h e r ea s1 1 b-
HSD1 knock-out mice have decreased TNF- a mRNA
in adipose tissue [24]. Recently, knock-down of 11b-
HSD1 in pre-adipocytes has resulted in the decreased
expression of IL-6 [25]. Although WNIN/Ob obese rats
have elevated 11b-HSD1 activity in adipose tissue,
plasma levels of TNF-a and IL-6 levels are not elevated.
This contrasting observation could be due to activation
of other signaling mechanisms that can downregulate
expression of TNF- a and IL-6 in adipose and other tis-
sues. Secretion of MCP-1 by adipose tissue is the key
step in the recruitment of macrophages. In obesity, ele-
vated plasma and adipose MCP-1 levels are reported
along with increased tissue macrophages [26]. 11b-
HSD1 inhibition has been shown to decrease MCP-1
expression in adipose tissue [27]. Although plasma
MCP-1 levels showed a trend towards increase, the
observation is not statistically significant due to large
variation.
Liver exhibits significant 11b-HSD1 activity and is also
the main organ for the conversion of inactive glucocorti-
coids to active glucocorticoids [28]. Functional studies
have shown that transgenic overexpression of 11b-HSD1
in liver results in insulin resistance, hepatic steatosis
without causing obesity [29]. On the contrary, 11b-
HSD1 knock-out mice are resistant to high fat diet-
induced metabolic syndrome [20]. Previous studies
involving rodent models of obesity and in obese humans
have reported lower 11b-HSD1 activity in liver, which is
considered to be a compensatory mechanism to improve
obesity associated insulin resistance [4-6]. In the present
study, WNIN/Ob obese rats displayed lower hepatic
11b-HSD1 activity, which is in line with the previous
observations.
Recently, we have also studied the impact of nutrients
like vitamin A and polyunsaturated fattyacids on 11b-
HSD1 activity in WNIN/Ob obese rats. Chronic challen-
ging with vitamin A enriched diet, decreased 11b-HSD1
activity in liver and adipose tissue of obese rats, with
concomitant reduction in adiposity (unpublished data).
A decreased trend in 11b-HSD1 activity in adipose tis-
sue of obese rats was also observed with chronic feeding
of diet-rich in n-6 polyunsaturated fattyacids (unpub-
lished data).
In conclusion, WNIN/Ob obese rats have elevated
levels of circulatory glucocorticoids, lower hepatic 11b-
HSD1 activity and higher omental and subcutaneous
HSD1 activity. WNIN/Ob obese rats show several bio-
chemical and physiological features similar to human
obesity, particularly with regard to tissue glucocorticoid
metabolism. Based on these observations, we propose
that, WNIN/Ob obese rat not only serve as a good
model to study the role of 11b-HSD1 in the develop-
ment of obesity and metabolic syndrome, but also to
study the effect of 11b-HSD1 inhibitors and 11b-HSD1
regulating nutrients in the amelioration of obesity and
metabolic syndrome.
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